The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression
Abstract
Objective: To identify patients’ perceptions of the value of psilocybin as a treatment for depression. Method: Twenty patients enrolled in an open-label trial of psilocybin for treatment-resistant depression participated in a semistructured interview at 6-month follow-up. Thematic analysis was used to identify patients’ experiences of the treatment and how it compared with previous treatments. Results: Two main change processes were identified in relation to the treatment. The first concerned change from disconnection (from self, others, and world) to connection, and the second concerned change from avoidance (of emotion) to acceptance. A third theme concerned comparison between psilocybin and conventional treatments. Patients reported that medications and some short-term talking therapies tended to reinforce their sense of disconnection and avoidance, whereas treatment with psilocybin encouraged connection and acceptance. Conclusions: These results suggest that psilocybin treatment for depression may work via paradigmatically novel means, antithetical to antidepressant medications, and some short-term talking therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A limitation of the CEQ is that it measures challenging emotions, memories, or both without addressing their potential resolution. Therefore, it cannot assess the potential value of overcoming any emotional challenges experienced under the influence of psychedelics (Watts et al., 2017).”
From Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics (2024) · cites this paper as Watts et al., 2017
In the citing paper
“Therapeutic outcomes appear strongly influenced by psychological “set” (mindset, expectations, preparation), environmental “setting,” and structured post-session integration (96, 99, 107, 108), highlighting the central role of context, support, and integration in optimizing benefit.”
From The therapeutic role of self-transcendence in moral injury recovery: theory, mechanisms, and clinical implications (2026) · cites this paper as [99]
In the citing paper
“In qualitative interviews, participants identified this tri-dimensional factor as a key element underlying the therapeutic effect of PAT [61, 62], including reduced craving and substance use in individuals with addiction [62].”
In the citing paper
“These emotions largely cohered with previous observations in other psilocybin studies (36–42).”
In the citing paper
“These outcomes are in line with previous reports from participants of clinical trials, who described a notable shift from emotional avoidance to acceptance, after receiving psilocybin-assisted psychotherapy for treatment-resistant depression [57].”
From The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol (2022) · cites this paper as [57]
In the citing paper
“Their use can help individuals break through emotional barriers, confront past traumas, and develop a deeper sense of self-awareness and connection with others (Watts et al. 2017;Carhart-Harris et al. 2018).”
From Authenticity and Love Drugs: Insights from Psychedelic Therapy (2026) · cites this paper as Watts et al. 2017
In the citing paper
“After treatment, many reported to be able to “re-connect” with family members, friends, strangers, and even people who had wronged them.”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [32]
In the citing paper
“Patients identified this increased connection as one of two main change processes in relation to treatment (32)”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [32]
In the citing paper
“Yet, the same patients reported that they experienced a sense of disconnection from others as particularly distressing before psilocybin-assisted treatment (32).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [32]
Citations
Cites
(1998) · Sage eBooks · Cited by 38,631
Basics of Qualitative Research (3rd ed.): Techniques and Procedures for Developing Grounded Theory
Corbin, J., & Strauss, A. (2008) · SAGE · doi:10.4135/9781452230153 · Cited by 12,136
Successful Qualitative Research: A practical guide for beginners
Jamieson, J., Braun, V., & Clarke, V. (2014) · QMiP Bulletin · doi:10.53841/bpsqmip.2014.1.18.39 · Cited by 6,673
Successful qualitative research: A practical guide for beginners
(2016) · QMiP Bulletin · doi:10.53841/bpsqmip.2016.1.21.48 · Cited by 4,033
Client-Centered Therapy: Its Current Practice, Implications and Theory
Rogers, C. R. (1951) · Cited by 2,416
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 4×
“…formal, quantitative analyses of the utility of psilocybin (Carhart-Harris, Bolstridge, et al., 2016; Carhart-Harris, 2017; Gasser et al., 2014; Griffiths et al., 2016; Ross et al., 2016) and should help inform and enrich understanding of this novel treatment and its mechanisms of action,…”
InfluentialClient-centered therapy; its current practice, implications, and theory.
Miles, D. W. (1952) · Psychological Bulletin · doi:10.1037/h0053095 · Cited by 2,122
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
How important are the common factors in psychotherapy? An update
Wampold, B. E. (2015) · World Psychiatry · doi:10.1002/wps.20238 · Cited by 1,728 · cited 1×
“…to play a role in determining treatment outcomes (Greenberg, Constantino, & Bruce, 2006; Visla, Constantino, Newkirk, Ogrodniczuk, & Söchting, 2016; Wampold, 2015; Wampold et al., 2005) and it is likely that many of the patients in this trial had positive expectations and/or experienced a positive…”
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Research works printed but not linked: 5
- Frankl V. E., 1961, Confinia Psychiatrica, 4, 99
- Goldsmith N., 2011, Psychedelic healing: The promise of entheogens for psychotherapy and spiritual development
- Grof S., 1980, LSD psychotherapy
- Meckel Fischer F., 2015, Therapy with substance: Psycholytic psychotherapy in the twenty first century
- Stolaroff M., 2004, The secret chief revealed: Conversations with Leo Zeff
Cited by
Sorted by citations
Items 101–200 of 585
Mans, K., Kettner, H., Erritzøe, D., Haijen, E. C. H. M., Kaelen, M., & Carhart-Harris, R. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.647909 · Cited by 63
Self-citationZeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.105 · Cited by 68
Self-citationNoorani, T. N., Bedi, G., & Muthukumaraswamy, S. D. (2023) · Psychological Medicine · doi:10.1017/s0033291723001289 · Cited by 64
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58
Neuropharmacological modulation of the aberrant bodily self through psychedelics
Ho, J. T., Preller, K. H., & Lenggenhager, B. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.12.006 · Cited by 62
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
Barba, T., Buehler, S., Kettner, H., Radu, C., Cunha, B. G., Nutt, D. J., Erritzøe, D., Roseman, L., & Carhart-Harris, R. L. (2022) · BJPsych Open · doi:10.1192/bjo.2022.565 · Cited by 62
Self-citationKopra, E. I., Ferris, J., WINSTOCK, A. R., Kuypers, K. P. C., Young, A. H., & Rucker, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158245 · Cited by 67
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique
Mosurinjohn, S. C., Roseman, L., & Girn, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1077311 · Cited by 64
Psilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
Luoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.10.003 · Cited by 56
Close, J. B., Hajien, E. C., Watts, R., Roseman, L., & Carhart-Harris, R. L. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2020.01.005 · Cited by 54
Self-citationAgin-Liebes, G., Zeifman, R., Luoma, J. B., Garland, E. L., Campbell, W. K., & Weiss, B. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221080165 · Cited by 54
“…self-transcendent positive emotions (e.g. gratitude, love, joy, and awe; Agin-Liebes et al., 2021; Belser et al., 2017; Swift et al., 2017; Watts et al., 2017), may create a context for enhanced flexibility or reappraisal to occur by rendering engagement with difficult psychological…”
BackgroundAgin-Liebes, G., Ekman, E., Anderson, B., Malloy, M., Haas, A., & Woolley, J. (2024) · Journal of Humanistic Psychology · doi:10.1177/00221678211022949 · Cited by 51
Wießner, I., Falchi-Carvalho, M., Palhano-Fontes, F., Feilding, A., Ribeiro, S. T. G., & Tófoli, L. F. (2021) · Psychological Medicine · doi:10.1017/s0033291721002531 · Cited by 54
Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications
O’Callaghan, C. C., Hubik, D. J., Dwyer, J. L., Williams, M. L., & Ross, M. (2020) · Journal of Music Therapy · doi:10.1093/jmt/thaa006 · Cited by 57
Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics
Glowacki, D. R., Williams, R. R., Wonnacott, M., Maynard, O., Freire, R., Pike, J. E., & Chatziapostolou, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-12637-z · Cited by 64
Review of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 60
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 61
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 52
Weiss, B., Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L., & Erritzoe, D. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.749788 · Cited by 47
Self-citationBreeksema, J. J., Niemeijer, A. R., Kuin, B., Veraart, J. K. E., Kamphuis, J., Schimmel, N., van den Brink, W., Vermetten, E. H. G. J. M., & Schoevers, R. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.948115 · Cited by 50
Brennan, B., Kelman, A. R., & Belser, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0007 · Cited by 50
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Bezo, A., Piolino, P., & Benyamina, A. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106086 · Cited by 53
Ayahuasca’s Antidepressant Effects Covary with Behavioral Activation as Well as Mindfulness
Mian, M. N., Altman, B. R., & Earleywine, M. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1674428 · Cited by 47
Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences
Kähönen, J. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1104627 · Cited by 50
Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.01.002 · Cited by 51
Seeing without self: Discovering new meaning with psychedelic-assisted psychotherapy
Fischman, L. G. (2019) · Neuropsychoanalysis · doi:10.1080/15294145.2019.1689528 · Cited by 52
Kałużna, A., Schlosser, M., Craste, E. G., Stroud, J., & Cooke, J. E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00199 · Cited by 53
Hayes, S. C., Law, S., Malady, M., Zhu, Z., & Bai, X. (2019) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.005 · Cited by 49
Bornemann, J., Close, J. B., Spriggs, M. J., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735427 · Cited by 48
Self-citationMindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43
“While research is still emerging, some studies suggest that both approaches may enhance empathy, compassion, and social connectedness [55, [76, 77] as well as increased self-compassion and prosocial attitudes [78, 79].”
BackgroundPenn, A., Phelps, J., Rosa, W. E., & Watson, J. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211011013 · Cited by 45
Michael, P., Luke, D. P., & Robinson, O. C. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.720717 · Cited by 46
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723001514 · Cited by 48
Self-citationWolff, M., Evens, R., Mertens, L. J., Schmidt, C., Beck, J. L., Rutrecht, H. M., Cherniak, A. D., Gründer, G., & Jungaberle, H. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249698 · Cited by 40
Relational Processes in Ayahuasca Groups of Palestinians and Israelis
Roseman, L., Ron, Y., Saca, A., Ginsberg, N. L., Luan, L. X., Karkabi, N., Doblin, R., & Carhart-Harris, R. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.607529 · Cited by 43
Self-citationKuc, J., Kettner, H., Rosas, F. E., Erritzøe, D., Haijen, E. C. H. M., Kaelen, M., Nutt, D., & Carhart-Harris, R. L. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05999-1 · Cited by 41
Self-citationLafrance, A., Strahan, E., Bird, B. M., St. Pierre, M., & Walsh, Z. (2021) · Journal of Humanistic Psychology · doi:10.1177/00221678211048049 · Cited by 40
Koslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 42
Villiger, D., & Trachsel, M. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108816 · Cited by 43
Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy
Thal, S. B., Bright, S. J., Sharbanee, J. M., Wenge, T., & Skeffington, P. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.617224 · Cited by 38
Do psychedelics change beliefs?
McGovern, H. T., Leptourgos, P., Hutchinson, B. T., & Corlett, P. R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06153-1 · Cited by 40
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Argento, E., Braschel, M. C., Walsh, Z., Socias, M. E., & Shannon, K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118798610 · Cited by 38
Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year
Simonsson, O., Hendricks, P. S., Carhart-Harris, R. L., Kettner, H., & Osika, W. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16715 · Cited by 37
Self-citationMoral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics
Langlitz, N., Dyck, E., Scheidegger, M., & Repantis, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.680064 · Cited by 41
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis
Kelly, J. R., Clarke, G. A., Harkin, A., Corr, S. C., Galvin, S. D., Pradeep, V., Cryan, J. F., O’Keane, V., & Dinan, T. G. (2022) · International Journal of Clinical and Health Psychology · doi:10.1016/j.ijchp.2022.100349 · Cited by 40
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 35
Psilocybin and Other Classic Psychedelics in Depression
Nutt, D., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 39
Self-citationCastelhano, J., Lima, G., Teixeira, M., Soares, C., Pais, M. L., & Castelo-Branco, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739053 · Cited by 41
Hovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231200019 · Cited by 33
“Therefore, it cannot assess the potential value of overcoming any emotional challenges experienced under the influence of psychedelics (Watts et al., 2017).”
BackgroundPsychedelics in the treatment of unipolar and bipolar depression
Bosch, O. G., Halm, S., & Seifritz, E. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00265-5 · Cited by 38
Scalabrini, A., Mucci, C., & Northoff, G. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.980353 · Cited by 35
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G. K., Ching, T. H. W., Belser, A., & Pittenger, C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12135 · Cited by 44
Psilocybin-Assisted Compassion Focused Therapy for Depression
Pots, W. T. M., & Chakhssi, F. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.812930 · Cited by 35
How do serotonergic psychedelics treat depression: The potential role of neuroplasticity
Artin, H., Zisook, S., & Ramanathan, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i6.201 · Cited by 33
Stupak, R., & Dobroczyński, B. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126625 · Cited by 35
Presence, Trust, and Empathy: Preferred Characteristics of Psychedelic Carers
Thal, S. B., Engel, L. B., & Bright, S. J. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221081380 · Cited by 34
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 37
Lake, S., & Lucas, P. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0002 · Cited by 34
Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca
Weiss, B., Wingert, A., Erritzoe, D., & Campbell, W. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-36184-3 · Cited by 33
Argento, E., Socias, M. E., Hayashi, K., Choi, J., Mackay, L., Christie, D., Milloy, M., & DeBeck, K. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103518 · Cited by 35
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 41
Self-citationPsychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 33
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32
Entity encounters and the therapeutic effect of the psychedelic mystical experience
Lutkajtis, A. (2021) · Journal of Evolutionary Psychology · doi:10.1556/2054.2020.00143 · Cited by 37
Psychedelics alter metaphysical beliefsPreprint
Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F. E., & Carhart-Harris, R. L. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/f6sjk · Cited by 34
Self-citationFrymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30
Soares, C., Mier, G. G., Castelhano, J., & Castelo-Branco, M. S. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105325 · Cited by 30
Whitfield, H. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727572 · Cited by 32
Psilocybin occasioned mystical‐type experiences
James, E., Robertshaw, T. L., Hoskins, M. D., & Sessa, B. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2742 · Cited by 36
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Modlin, N. L., Miller, T. M., Rucker, J., Kirlić, N., Lennard-Jones, M., Schlosser, D. A., & Aaronson, S. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.077 · Cited by 31
DellaCrosse, M., Pleet, M., Morton, E., Ashtari, A., Sakai, K., Woolley, J., & Michalak, E. (2022) · PLOS ONE · doi:10.1371/journal.pone.0279073 · Cited by 28
Animal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 30
Perkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 33
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D. J., & Spriggs, M. J. (2023) · Neuroethics · doi:10.1007/s12152-023-09536-z · Cited by 31
Self-citationThal, S. B., Baker, P., Marinis, J., Wieberneit, M., Sharbanee, J. M., Bruno, R., Skeffington, P., & Bright, S. J. (2023) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2945 · Cited by 32
Tripping over the other: Could psychedelics increase empathy?
Blatchford, E., Bright, S. J., & Engel, L. B. (2020) · Journal of Evolutionary Psychology · doi:10.1556/2054.2020.00136 · Cited by 30
Classic psychedelics, health behavior, and physical health
Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253221135363 · Cited by 30
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
Ponomarenko, P., Seragnoli, F., Calder, A. E., Oehen, P., & Hasler, G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231155117 · Cited by 31
Kaup, K., Vasser, M., Tulver, K., Munk, M., Pikamäe, J., & Aru, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1088896 · Cited by 31
Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V., Ramaekers, J. G., & Mason, N. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.883869 · Cited by 26
“Psychedelic drugs have been found to modulate social cognition and interpersonal experiences (87), and individuals whom have undergone psychedelic therapy with psychological support have indicated that increased feelings of social connectedness were an important aspect of the therapeutic process (88).”
BackgroundPsilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis
Irizarry, R., Winczura, A., Dimassi, O., Dhillon, N., Minhas, A., & Larice, J. (2022) · Cureus · doi:10.7759/cureus.31796 · Cited by 26
Bernal, A. M. O., Raison, C. L., Lancelotta, R., & Davis, A. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1049643 · Cited by 32
Wall, M. B., Demetriou, L., Giribaldi, B., Roseman, L., Ertl, N., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230751 · Cited by 27
Self-citationPadawer-Curry, J. A., Krentzman, O. J., Kuo, C., Wang, X., Bice, A. R., Nicol, G. E., Snyder, A. Z., Siegel, J. S., McCall, J. G., & Bauer, A. Q. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02069-z · Cited by 30
Heinzerling, K. G., Sergi, K., Linton, M., Rich, R., Youssef, B., Bentancourt, I., Bramen, J. E., Siddarth, P., Schwartzberg, L., & Kelly, D. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1215972 · Cited by 25
Stocker, K., Hartmann, M., Ley, L., Becker, A., Holze, F., & Liechti, M. E. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231199112 · Cited by 29
Insights on psychedelics: A systematic review of therapeutic effects
Kugel, J., Laukkonen, R., Yaden, D. B., Yücel, M., & Liknaitzky, P. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106117 · Cited by 32
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 24
Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives
Messell, C., Summer, L., Bonde, L. O., Beck, B. D., & Stenbæk, D. S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.873455 · Cited by 30
Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia
Irvine, A., Luke, D. P., Harrild, F., Gandy, S., & Watts, R. (2023) · Psychoactives · doi:10.3390/psychoactives2020012 · Cited by 25
Self-citationHistoricizing psychedelics: counterculture, renaissance, and the neoliberal matrix
Petrement, M. S. (2023) · Frontiers in Sociology · doi:10.3389/fsoc.2023.1114523 · Cited by 28
A lexicon for psychedelic research and treatment
Nutt, D. J., Erritzøe, D., Schlag, A. K., Luke, D. P., Mash, D. C., Uchida, H., Aday, J. S., Rucker, J., Galindo, L., Sweeney, M., et al. (2025) · Drug Science Policy and Law · doi:10.1177/20503245251380511 · Cited by 24
Self-citationGattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 24
Murphy, R. J., Sumner, R. L., Evans, W., Menkes, D. B., Lambrecht, I., Ponton, R., Sundram, F., Hoeh, N. R., Ram, S., Reynolds, L., et al. (2021) · Trials · doi:10.1186/s13063-021-05243-3 · Cited by 25
Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder
Ledwos, N., Rodas, J. D., Husain, M. I., Feusner, J. D., & Castle, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140009 · Cited by 28
Experiences of psilocybin treatment for clinical conditions: A qualitative meta‐synthesis
Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. J. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13127 · Cited by 23
Psychedelics and neonihilism: connectedness in a meaningless world
Plesa, P., & Petranker, R. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1125780 · Cited by 22
Stocker, K., & Liechti, M. E. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265352 · Cited by 19
Metadata
- Authors
- Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Watts, Rosalind
- Venue
- Journal of Humanistic Psychology
- Publisher
- SAGE Publications
- Published
- 2017-06-19
- Volume
- 57
- Issue
- 5
- Pages
- 520-564
- ISSN
- 0022-1678 (ISSN-L)
- 1552-650X
- OpenAlex
- W2644260506
- Cited by
- 589
- References
- 54
- Citations by year
- 2026: 80 · 2025: 86 · 2024: 87 · 2023: 100 · 2022: 84 · 2021: 72 · 2020: 34 · 2019: 19 · 2018: 20 · 2017: 6
- FWCI
- 26.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Humanistic Psychology (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, treatment-resistant depression, patient experience, connectedness, acceptance, disconnection, emotional avoidance, antidepressants, psychotherapy, psychedelic therapy, mechanisms of change
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
